Related Experiment Video
Updated: May 6, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
22.1K
Idiopathic interstitial lung diseases - treatment options
Summary
Idiopathic interstitial pneumonias (IIPs) are rare lung diseases with new classifications. While treatments for idiopathic pulmonary fibrosis (IPF) are advancing, other IIPs still rely on limited evidence-based therapies.
Area of Science:
- Pulmonology
- Rare Diseases
- Respiratory Medicine
Background:
- Idiopathic interstitial pneumonias (IIPs) encompass a diverse range of rare lung diseases.
- These conditions are defined by unique radiological and histological features.
- The 2025 classification refines the definition of individual IIP entities.
Purpose of the Study:
- To review the updated classification of IIPs.
- To summarize current therapeutic strategies for IIPs.
- To highlight the role of non-pharmacological interventions.
Main Methods:
- Literature review of recent classifications and clinical trials.
- Analysis of therapeutic approaches for common and rare IIPs.
- Examination of disease complications and management strategies.
Main Results:
- The 2025 classification incorporates new entities but doesn't change current treatments.
- Antifibrotic drugs (pirfenidone, nintedanib) improve outcomes in idiopathic pulmonary fibrosis (IPF).
- Treatment for other IIPs, like NSIP, relies on corticosteroids and immunosuppressants with limited evidence.
Conclusions:
- Ongoing research may offer new therapeutic options for IIPs.
- Pulmonary hypertension and acute exacerbations are significant complications.
- Oxygen therapy, pulmonary rehabilitation, and lung transplantation are crucial supportive measures.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
4.0K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
4.0K
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
01:20COPD: Pathogenesis and Clinical Features
2.1K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.1K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.3K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K